Today: 21 May 2026
Stock Market Today: Hot PPI Jolts Wall Street Futures Ahead of Fed Decision; Micron Earnings Up Next

Stock Market Today: Hot PPI Jolts Wall Street Futures Ahead of Fed Decision; Micron Earnings Up Next

NEW YORK, March 18, 2026, 09:05 EDT

  • U.S. stock futures slipped into the red after February’s producer price data came in hotter than anticipated, denting expectations for an imminent rate cut from the Federal Reserve.
  • Markets are betting the Fed keeps rates stuck at 3.50%-3.75% this Wednesday, but attention has shifted to the fresh dot plot and what Chair Jerome Powell will say at his press conference.
  • Brent crude held north of $100 a barrel, even as Iraq eased some export pressure. Traders eyed Micron’s post-close results, keeping the chip names active.

U.S. stock futures slipped after a surprising jump in wholesale inflation added some uncertainty ahead of the Federal Reserve’s policy call this day. Dow e-minis fell 115 points as of 8:36 a.m. ET; S&P 500 and Nasdaq 100 futures were also in the red by 9:05 a.m. EDT.

This time, the Fed’s expected pause isn’t just another placeholder. Market attention is glued to the dot plot—where policymakers sketch out their own rate projections—and to any hint the Iran war’s oil price spike could push rate cuts further out. Now, futures are pricing in just a single quarter-point reduction for 2026, set for September.

The Producer Price Index climbed 0.7% in February from the previous month, up 3.4% year-over-year—each figure beating analyst expectations. Stripping out food and energy, core PPI advanced 0.5% on the month and posted a 3.9% annual gain.

Traders aren’t really expecting a rate move today—they’re zeroed in on the Fed’s tone about what’s ahead. The statement lands at 2 p.m. EDT, and Powell steps up at 2:30 p.m. Tony Sycamore at IG notes that the current dot plot suggests just one cut this year, though he flags a risk that the projections turn more hawkish if officials see the oil shock making inflation tougher to shake.

Diane Swonk, chief economist at KPMG, echoed that sentiment. In her view, these forecasts come “amidst a cloud of uncertainty,” with expectations pointing to weaker growth, stickier inflation, and more joblessness—a tough set of challenges for a central bank already divided on how to balance employment support against renewed inflation risks. Reuters

Oil remains the key variable here. Brent crude added 0.6%, last quoted at $104.02 a barrel as of 1155 GMT. U.S. West Texas Intermediate sat at $94.93, despite Iraq restarting some pipeline flows to Turkey. MUFG analyst Soojin Kim noted the bounce is muted: Iraq’s production lags well below pre-crisis marks, and the Strait of Hormuz remains mostly choked off.

The spotlight shifts to Micron after the close. The chipmaker’s earnings have already helped calm tech nerves, paired with news that Nvidia got the green light from China to sell a top-tier AI chip. Whatever Micron says will ripple across the memory sector—think Samsung, SK Hynix—traders are watching.

On Wednesday, Samsung co-CEO Jun Young-hyun described what he called an “unprecedented supercycle” for chips, crediting heavy AI data centre investment as the catalyst. That doesn’t answer the larger macroeconomic picture, but it does shed light on why investors are sticking with chip stocks even as the outlook for rates turns gloomier. Reuters

Still, there’s room for a swing in either direction. Should Powell wave off the oil move as a blip and the dot plot still support a single cut, futures might claw back some of their earlier losses. On the other hand, if policymakers suggest that rate hikes are just as much on the table as cuts—a scenario BNP Paribas has warned about—both stocks and Treasuries could see fresh downside.

The simple bet on a Fed rate cut isn’t holding up. As the bell approaches, traders are juggling hotter wholesale inflation, Brent crude trading north of $100, and a Fed meeting that no longer feels routine.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Oklo Stock Rises After Earnings Show Wider 2025 Loss, Cash Hoard and Reactor Approvals
Previous Story

Oklo Stock Rises After Earnings Show Wider 2025 Loss, Cash Hoard and Reactor Approvals

Lumentum Stock Jumps on AI Optics Forecast at OFC Despite Nvidia’s Copper Stance
Next Story

Lumentum Stock Jumps on AI Optics Forecast at OFC Despite Nvidia’s Copper Stance

Go toTop